Natco Pharma posts Rs 715.3 crore of Profit after tax for year ended March 31st, 2023
The profit for the fourth quarter, on a consolidated basis was INR 275.8 Crore, as against a loss of INR 50.5 Crore last year fourth quarter.;
Hyderabad: Hyderabad-based NATCO Pharma Limited has recorded consolidated total revenue of INR 2811.7 Crore for the year ended on 31st March, 2023, as against INR 2043.8 Crore for the last year, reflecting 37.6% growth.
The net profit for the period, on a consolidated basis, was INR 715.3 Crore, as against INR 170.0 Crore last year. The increase in revenue and profits for the year was driven by business growth in the US market and growth in the company's subsidiaries in Canada & Brazil.
Natco Crop Health Division started off well with strong growth potential in ensuing years. For the fourth quarter (Q4) ended March 31st, 2023, the company recorded a net revenue of INR 926.9 Crore, on a consolidated basis, as against INR 610.6 Crore during Q4, FY 2022. The profit for the fourth quarter, on a consolidated basis was INR 275.8 Crore, as against a loss of INR 50.5 Crore last year fourth quarter.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.